163 related articles for article (PubMed ID: 16680013)
1. Glycogen synthase kinase-3beta inhibitors protect against the organ injury and dysfunction caused by hemorrhage and resuscitation.
Dugo L; Abdelrahman M; Murch O; Mazzon E; Cuzzocrea S; Thiemermann C
Shock; 2006 May; 25(5):485-91. PubMed ID: 16680013
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting glycogen synthase kinase 3beta in sepsis.
Dugo L; Collin M; Allen DA; Patel NS; Bauer I; Mervaala E; Louhelainen M; Foster SJ; Yaqoob MM; Thiemermann C
Novartis Found Symp; 2007; 280():128-42; discussion 142-6, 160-4. PubMed ID: 17380792
[TBL] [Abstract][Full Text] [Related]
3. GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat.
Dugo L; Collin M; Allen DA; Patel NS; Bauer I; Mervaala EM; Louhelainen M; Foster SJ; Yaqoob MM; Thiemermann C
Crit Care Med; 2005 Sep; 33(9):1903-12. PubMed ID: 16148458
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of glycogen synthase kinase (GSK)-3-β improves liver microcirculation and hepatocellular function after hemorrhagic shock.
Jellestad L; Fink T; Pradarutti S; Kubulus D; Wolf B; Bauer I; Thiemermann C; Rensing H
Eur J Pharmacol; 2014 Feb; 724():175-84. PubMed ID: 24389157
[TBL] [Abstract][Full Text] [Related]
5. Insulin reduces the multiple organ injury and dysfunction caused by coadministration of lipopolysaccharide and peptidoglycan independently of blood glucose: role of glycogen synthase kinase-3beta inhibition.
Dugo L; Collin M; Allen DA; Murch O; Foster SJ; Yaqoob MM; Thiemermann C
Crit Care Med; 2006 May; 34(5):1489-96. PubMed ID: 16557150
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of glycogen synthase kinase-3β attenuates organ injury and dysfunction associated with liver ischemia-reperfusion and thermal injury in the rat.
Rocha J; Figueira ME; Barateiro A; Fernandes A; Brites D; Pinto R; Freitas M; Fernandes E; Mota-Filipe H; Sepodes B
Shock; 2015 Apr; 43(4):369-78. PubMed ID: 25394244
[TBL] [Abstract][Full Text] [Related]
7. Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta.
Whittle BJ; Varga C; Pósa A; Molnár A; Collin M; Thiemermann C
Br J Pharmacol; 2006 Mar; 147(5):575-82. PubMed ID: 16314851
[TBL] [Abstract][Full Text] [Related]
8. Treatment with the glycogen synthase kinase-3beta inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus.
Collino M; Thiemermann C; Mastrocola R; Gallicchio M; Benetti E; Miglio G; Castiglia S; Danni O; Murch O; Dianzani C; Aragno M; Fantozzi R
Shock; 2008 Sep; 30(3):299-307. PubMed ID: 18323734
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of NADPH oxidase reduce the organ injury in hemorrhagic shock.
Abdelrahman M; Mazzon E; Bauer M; Bauer I; Delbosc S; Cristol JP; Patel NS; Cuzzocrea S; Thiemermann C
Shock; 2005 Feb; 23(2):107-14. PubMed ID: 15665724
[TBL] [Abstract][Full Text] [Related]
10. Effects of inhibitors of the activity of poly (ADP-ribose) synthetase on the organ injury and dysfunction caused by haemorrhagic shock.
McDonald MC; Filipe HM; Thiemermann C
Br J Pharmacol; 1999 Nov; 128(6):1339-45. PubMed ID: 10578150
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of glycogen synthase kinase-3beta attenuates the development of carrageenan-induced lung injury in mice.
Cuzzocrea S; Crisafulli C; Mazzon E; Esposito E; Muià C; Abdelrahman M; Di Paola R; Thiemermann C
Br J Pharmacol; 2006 Nov; 149(6):687-702. PubMed ID: 17016509
[TBL] [Abstract][Full Text] [Related]
12. Acute treatment with bone marrow-derived mononuclear cells attenuates the organ injury/dysfunction induced by hemorrhagic shock in the rat.
Nandra KK; Takahashi K; Collino M; Benetti E; Wong WS; Goh FY; Suzuki K; Patel NS; Thiemermann C
Shock; 2012 Jun; 37(6):592-8. PubMed ID: 22392145
[TBL] [Abstract][Full Text] [Related]
13. GSK-3β inhibition attenuates CLP-induced liver injury by reducing inflammation and hepatic cell apoptosis.
Zhang H; Wang W; Fang H; Yang Y; Li X; He J; Jiang X; Wang W; Liu S; Hu J; Liu A; Dahmen U; Dirsch O
Mediators Inflamm; 2014; 2014():629507. PubMed ID: 25525303
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of GSK-3beta decreases NF-kappaB-dependent gene expression and impairs the rat liver regeneration.
Chen H; Yang S; Yang Z; Ma L; Jiang D; Mao J; Jiao B; Cai Z
J Cell Biochem; 2007 Dec; 102(5):1281-9. PubMed ID: 17427960
[TBL] [Abstract][Full Text] [Related]
15. Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3beta.
Collino M; Aragno M; Castiglia S; Tomasinelli C; Thiemermann C; Boccuzzi G; Fantozzi R
Diabetes; 2009 Jan; 58(1):235-42. PubMed ID: 18840784
[TBL] [Abstract][Full Text] [Related]
16. GSK-3beta inhibitors reduce protein degradation in muscles from septic rats and in dexamethasone-treated myotubes.
Evenson AR; Fareed MU; Menconi MJ; Mitchell JC; Hasselgren PO
Int J Biochem Cell Biol; 2005 Oct; 37(10):2226-38. PubMed ID: 16051512
[TBL] [Abstract][Full Text] [Related]
17. Glycogen synthase kinase 3beta inhibition reduces the development of nonseptic shock induced by zymosan in mice.
Cuzzocrea S; Di Paola R; Mazzon E; Crisafulli C; Genovese T; Muià C; Abdelrahman M; Esposito E; Thiemermann C
Shock; 2007 Jan; 27(1):97-107. PubMed ID: 17172987
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of glycogen synthase kinase-3β prevents activation of focal adhesion kinase after ischemia/reperfusion of the rat lung.
Waldow T; Witt W; Matschke K
Clin Hemorheol Microcirc; 2010; 46(2-3):169-81. PubMed ID: 21135492
[TBL] [Abstract][Full Text] [Related]
19. Diabetes mellitus abrogates the cardioprotection of sufentanil against ischaemia/reperfusion injury by altering glycogen synthase kinase-3β.
Chen QL; Gu EW; Zhang L; Cao YY; Zhu Y; Fang WP
Acta Anaesthesiol Scand; 2013 Feb; 57(2):236-42. PubMed ID: 22881281
[TBL] [Abstract][Full Text] [Related]
20. Glycogen synthase kinase 3beta in the nucleus accumbens core mediates cocaine-induced behavioral sensitization.
Xu CM; Wang J; Wu P; Zhu WL; Li QQ; Xue YX; Zhai HF; Shi J; Lu L
J Neurochem; 2009 Dec; 111(6):1357-68. PubMed ID: 19799712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
